



OPEN ACCESS

EDITED AND REVIEWED BY
D. P. Kreil,
University of Natural Resources and Life
Sciences, Vienna, Austria

*CORRESPONDENCE
Jie Zhang
✉ zhangjie123@bjmu.edu.cn

RECEIVED 30 November 2023
ACCEPTED 18 December 2023
PUBLISHED 05 January 2024

CITATION
Wu W-J, Liu Q, An P-G, Wang L, Zhang J-Y,
Chen Y, Zhang T and Zhang J (2024)
Corrigendum: Neoadjuvant tislelizumab
combined with chemotherapy in
locally advanced oral or oropharyngeal
squamous cell carcinoma: a real-world
retrospective study.
Front. Immunol. 14:1346845.
doi: 10.3389/fimmu.2023.1346845

COPYRIGHT
© 2024 Wu, Liu, An, Wang, Zhang, Chen,
Zhang and Zhang. This is an open-access
article distributed under the terms of the
[Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/).
The use, distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Corrigendum: Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: a real-world retrospective study

Wen-Jie Wu^{1,2,3}, Qian Liu^{1,2,3}, Pu-Gen An^{1,2,3}, Lin Wang^{1,2,3},
Jian-Yun Zhang^{2,3,4}, Yan Chen^{2,3,4}, Tong Zhang⁵
and Jie Zhang^{1,2,3*}

¹Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing, China, ²National Center of Stomatology & National Clinical Research Center for Oral Diseases, Beijing, China, ³Central Laboratory, Peking University School and Hospital of Stomatology, Beijing, China, ⁴Department of Oral Pathology, Peking University School and Hospital of Stomatology, Beijing, China, ⁵Department of Oncology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China

KEYWORDS

neoadjuvant, immunotherapy, chemotherapy, head and neck, squamous cell carcinoma

A Corrigendum

Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: a real-world retrospective study

by Wu W-J, Liu Q, An P-G, Wang L, Zhang J-Y, Chen Y, Zhang T and Zhang J (2023) *Front. Immunol.* 14:1282629. doi: 10.3389/fimmu.2023.1282629

Text Correction

In the published article, there was an error. Some of the statements in the article about the results in Figure 2A were inappropriate.

A correction has been made to **Results**, *Efficacy of neoadjuvant therapy*, Line 3-9, Paragraph 2, Page 3. This sentence previously stated:

“A significant difference was observed in the median OS in the MPR (20 months) and non-MPR groups (16 months) respectively ($p = 0.0138$). In addition, the median DFS showed significant difference and in the MPR (18.5 months) and non-MPR groups (12 months), respectively, ($p < .001$) (Figure 2A).”

The corrected sentence appears below:

“A significant difference was observed in the OS between the MPR and non-MPR groups ($p = 0.0138$). In addition, the DFS showed a significant difference between the MPR and non-MPR groups ($p < .001$) (Figure 2A).”

In the published article, there was an error. Some of the statements in the article about the results in Figure 4B were inappropriate.

A correction has been made to **Results, Survival**, Line 4-9, Page 5. This sentence previously stated:

“Prognostic evaluation based on the PD-L1 CPS status revealed median OS durations of 22, 19, and 19 months for patients with PD-L1 CPS < 1, 1 ≤ PD-L1 CPS < 20, and PD-L1 CPS ≥ 20, respectively ($p = .3825$). Median DFS durations for the three groups were consistently 16 months ($p = .0244$) (Figure 4B).”

The corrected sentence appears below:

“Prognostic evaluation based on the PD-L1 CPS status revealed that there was no significant difference in the OS among patients with PD-L1 CPS < 1, 1 ≤ PD-L1 CPS < 20, and PD-L1 CPS ≥ 20 ($p = .3825$). But there was a significant difference in the DFS among the three groups ($p = .0244$) (Figure 4B).”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.